CAJ | 학술논문

为探讨应用亲属中HLA不全相合供体骨髓移植治疗白血病的疗效,选择性应用HLA 1～2个位点不合的血缘供体骨髓移植治疗白血病5例,并长期随访观察其远期疗效.结果5例患者中有3例无病存活1 340、1 160和900天以上,恢复了正常的生活、工作和学习,1例慢性髓性白血病患者无病存活3年,于嵌合造血状态下复发,正在供体淋巴细胞输注治疗中,1例表兄弟间2个位点不合移植患者因N度移植物抗宿主病和配型不合综合征致死.认为HLA不全相合的亲属供体骨髓移植治疗白血病是有应用前景的,然而对移植物抗宿主病的发生应予以足够的重视.
위탐토응용친속중HLA불전상합공체골수이식치료백혈병적료효,선택성응용HLA 1～2개위점불합적혈연공체골수이식치료백혈병5례,병장기수방관찰기원기료효.결과5례환자중유3례무병존활1 340、1 160화900천이상,회복료정상적생활、공작화학습,1례만성수성백혈병환자무병존활3년,우감합조혈상태하복발,정재공체림파세포수주치료중,1례표형제간2개위점불합이식환자인N도이식물항숙주병화배형불합종합정치사.인위HLA불전상합적친속공체골수이식치료백혈병시유응용전경적,연이대이식물항숙주병적발생응여이족구적중시.
In order to investigate the feasibility of HLA mismatched family marrow donor for treating the patients with leukemia, HLA one or two locus mismatched family marrow donor was used to treat 5 patients with leukemia and the long-term therapeutic effects were followed up in out-patients for 3 to 4 years. Three patients survived without diseases and with 100% of karnofy score more than 1 340, 1 160 and 900 days after transplant, respectively. One CML patient survived without disease over 3 years, now with hematological relapse in a situation of chimerism,and received donor lymphocyte infusion. One patient transplanted with HLA 2 locus mismatched cousin died of Ⅳ grade GVHD. One to two locus mismatched marrow donor is a good alternative one for treating leukemia patients of non-matched donor, but we should pay enough attention to the earlier occurrence of GVHD for this kind of transplant.